Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ)
CNY195.75
+17.80 (+10.00%)
CN SHZ Healthcare Biotechnology
Address
No. 6 Dongting 3rd Street
Tianjin, CN
Tianjin, CN
CEO
Hao Hong
Website
asymchem.com.cn
IPO
2016-11-22
ISIN CNE100002BZ6
Also trades on
Hong Kong Stock Exchange · 6821.HK (HKD)
Shenzhen Stock Exchange · 002821.SZ (CNY)
Description
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY195.75
+17.80 (+10.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
9M
Beta
0.11
Float Shares
221.05M
Free Float %
66.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.17% | -6.91% | -7.40% | +20.43% | +26.60% | +26.35% | +26.12% | -9.61% | -55.93% | +647.90% | +647.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
195.75
DCF (Levered)
43.21
-77.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
85% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | -1 |
Quality scores
Altman Z-Score
10.28
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+14.9% ★ Q1'26: +16.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+17.5% Q1'26: -5.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+12.2% ★ Q1'26: +9.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+19.5% ★ Q1'26: +18.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+10.9% ★ Q1'26: +11.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.6% ★ Q1'26: -1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.14× ★ Q1'26: 0.18× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 5 EPS Ana. |
Dec 2027 12 Rev. Ana. 5 EPS Ana. |
Dec 2028 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.42B
est: 1.42B (0.0%)
|
1.83B
est: 1.86B (-1.2%)
|
2.46B
est: 2.48B (-0.9%)
|
3.14B
est: 3.17B (-1.1%)
|
4.63B
est: 4.53B (+2.2%)
|
10.23B
est: 10.34B (-1.0%)
|
7.83B
est: 8.50B (-7.9%)
|
5.80B
est: 5.92B (-2.0%)
|
6.67B
est: 6.64B (+0.4%)
|
8.05B
7.97B – 8.14B
+21.2% YoY
|
9.65B
9.10B – 10.10B
+19.9% YoY
|
11.50B
11.09B – 11.85B
+19.2% YoY
|
| EBITDA |
495.29M
est: 404.40M (+22.5%)
|
495.60M
est: 527.85M (-6.1%)
|
665.78M
est: 705.31M (-5.6%)
|
922.03M
est: 901.00M (+2.3%)
|
1.24B
est: 1.29B (-3.5%)
|
3.43B
est: 2.94B (+16.9%)
|
2.65B
est: 2.41B (+9.7%)
|
1.07B
est: 1.66B (-35.6%)
|
1.85B
est: 1.87B (-0.8%)
|
2.26B
2.24B – 2.29B
+21.2% YoY
|
2.71B
2.55B – 2.84B
+19.9% YoY
|
3.23B
3.11B – 3.33B
+19.2% YoY
|
| EBIT |
420.13M
est: 331.56M (+26.7%)
|
392.12M
est: 432.78M (-9.4%)
|
543.55M
est: 578.27M (-6.0%)
|
767.37M
est: 738.71M (+3.9%)
|
1.05B
est: 1.06B (-1.0%)
|
3.11B
est: 2.41B (+29.2%)
|
2.22B
est: 1.98B (+12.2%)
|
618.69M
est: 1.32B (-53.1%)
|
1.30B
est: 1.48B (-12.3%)
|
1.79B
1.78B – 1.81B
+21.2% YoY
|
2.15B
2.03B – 2.25B
+19.9% YoY
|
2.56B
2.47B – 2.64B
+19.2% YoY
|
| Net Income |
341.29M
est: 379.22M (-10.0%)
|
428.30M
est: 493.88M (-13.3%)
|
553.86M
est: 607.95M (-8.9%)
|
719.74M
est: 774.08M (-7.0%)
|
1.07B
est: 1.02B (+4.4%)
|
3.30B
est: 3.03B (+8.9%)
|
2.27B
est: 2.39B (-5.0%)
|
948.95M
est: 988.51M (-4.0%)
|
1.13B
est: 1.13B (+0.6%)
|
1.39B
1.33B – 1.51B
+23.7% YoY
|
1.75B
1.61B – 1.90B
+25.5% YoY
|
2.16B
2.06B – 2.25B
+23.7% YoY
|
| SGA |
192.29M
est: 188.89M (+1.8%)
|
278.04M
est: 246.56M (+12.8%)
|
348.96M
est: 329.45M (+5.9%)
|
404.85M
est: 420.85M (-3.8%)
|
594.33M
est: 601.59M (-1.2%)
|
987.88M
est: 1.37B (-28.0%)
|
983.82M
est: 1.13B (-12.7%)
|
1.07B
est: 679.19M (+57.1%)
|
260.93M
est: 761.95M (-65.8%)
|
923.47M
914.21M – 933.71M
+21.2% YoY
|
1.11B
1.04B – 1.16B
+19.9% YoY
|
1.32B
1.27B – 1.36B
+19.2% YoY
|
| EPS |
1.08
est: 1.07 (+0.5%)
|
1.34
est: 1.40 (-4.3%)
|
1.73
est: 1.72 (+0.4%)
|
2.21
est: 2.19 (+0.7%)
|
3.15
est: 2.90 (+8.5%)
|
9.02
est: 8.59 (+5.0%)
|
6.26
est: 6.77 (-7.6%)
|
2.69
est: 2.76 (-2.5%)
|
3.16
est: 3.14 (+0.6%)
|
3.89
3.71 – 4.20
+23.7% YoY
|
4.88
4.50 – 5.30
+25.5% YoY
|
6.04
5.76 – 6.27
+23.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
843.87M
OE per share TTM
2.36
Owner's Yield
1.98%
Maintenance CapEx ratio
50.93%
Maint CapEx / Avg PPE
73.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 39 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.31% | 112.2K | 0.65% |
| 2 | JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L | 0.15% | 34.1K | 0.40% |
| 3 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.12% | 19.1K | 0.65% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.09% | 65.9K | 0.55% |
| 5 | State Street SPDR S&P China ETF GXC | 0.07% | 311.1K | 0.59% |
| 6 | Franklin FTSE China UCITS ETF FLXC.L | 0.02% | 381.4K | 0.19% |
| 7 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.02% | 12.9K | 0.15% |
| 8 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 163.3K | 0.46% |
| 9 | Schwab Emerging Markets Equity ETF SCHE | 0.01% | 920.5K | 0.06% |
| 10 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 16.6K | 0.58% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
135.4K
Shares Outstanding
333.04M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hao Hong | Founder, Chairman & Chief Executive Officer | 7M | — |
| Rui Yang | Co-CEO & Executive Director | 6M | female |
| Da Zhang | Chief Financial Officer, Chief Operating Officer, Senior Vice President & Executive Director | 5M | male |
| Liang Hong | Executive Vice President & Executive Director | 3M | — |
| Guoxi Zheng | Senior Vice President of EHS & UK Site Coordinator | — | — |
| Jiang Yingwei | Executive Vice President of Human Resources & Administration | — | male |
| Pingzhong Huang | Senior Vice President of Business Development & Project Management | — | — |
| Xiangke Xu | Senior Vice President and Board Secretary of Public Affairs & Regulatory Affairs & Legal Affairs | — | male |
| Changhai Tian | Senior Vice President of 5S Management | — | male |
| Yan Zhou | Senior Vice President of Quality Management | — | — |
| Chaoyong Chen | Executive Vice President of Manufacturing & Tech Transfer | — | male |
| Ching Kit Cheng | Joint Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002821.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
